London, UK and Carlsbad, CA, USA – 9 June 2022 – DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, has expanded its Commercial team, appointing Supriya Mathur to the newly created role of Global Head of Communications.
Supriya brings over 20 years of strategic communications experience, advising both private and public companies, especially in life sciences, through their development cycle. Having worked previously with Capital MSL (now Kekst CNC) and most recently as Director at Optimum Strategic Communications, she has extensive international consultancy experience, working with companies in Europe, the US and Asia.
During her career, Supriya has implemented global media and investor relations campaigns for clients throughout the healthcare and technology sectors and has worked on numerous transactions including financings, M&A and IPOs. At DNAe she joins the growing Commercial team, alongside Alison Howie, Vice President of Commercial.
Commenting on Supriya’s appointment, Samuel Reed, CEO of DNAe, said: “As we move ever closer to bringing our LiDia-SEQ™ diagnostic platform to patients and clinicians, our ability to effectively communicate the potentially life-changing benefits of our technology on the global stage becomes increasingly important. We are delighted to welcome Supriya to DNAe. Her extensive experience will further strengthen our fantastic team and support our continued evolution and growth.”
Supriya Mathur added: “DNAe’s technology has the potential to have a massive positive impact on patient care for a range of unmet clinical needs. I am excited to join at such an important time for the Company and look forward to working together with this talented team to ensure a strong communications strategy underpins our next phase of growth.”
Supriya’s appointment follows the appointments of Alison Howie as Vice President Commercial and Richard Hammond as Vice President Technology. The company is based in London, UK and Carlsbad, California and is actively expanding its team as it accelerates the development of its innovative “sample to sequence” platform.
- ENDS -
Samuel Reed, President, DNAe Group
Supriya Mathur, Global Head of Communications
Tel: +44 (0) 20 7036 2100
Instinctif Partners (media relations)
Tel: +44 (0) 20 7457 2013
Tim Watson / Katie Duffell
DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious disease and cancer testing and monitoring. It is developing the LiDia-SEQ™ system, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians. DNAe’s initial focus is on infectious disease diagnostics, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to directly detect and identify infections that lead to sepsis. This will provide clinicians with actionable information to help select the appropriate antibiotics to treat the disease. A pipeline of follow-on tests is in development for viruses and cancer testing and monitoring.
A private company, DNAe has operations in London, UK and Carlsbad, CA, USA. DNAe has received funding from The Biomedical Advanced Research and Development Authority (BARDA) to develop its diagnostic platform, initially for antimicrobial-resistant infections. DNAe’s major shareholder is Genting Berhad, a Malaysian-based global investor with a growing portfolio of investments in cutting-edge life sciences companies. www.dnae.com